Buprenorphine may be safer than methadone if treatment duration is longer, study suggests

April 20, 2018, University of Manchester
Credit: University of Manchester

The less commonly prescribed opioid substitute buprenorphine may be safer than methadone for problem opioid users, especially if used during the first month of treatment, according to a study which includes University of Manchester researchers.

The University of Bristol led study, funded by the National Institute for Health Research (NIHR) and published in the journal Addiction online today, analysed GP practice data for over 11,000 on opioid substitute linked to deaths data.

It assessed the relative risk of for the two treatments, compared to not being in treatment, over three time periods: in the first four weeks of starting treatment, during the rest of treatment, and in the first four weeks after treatment ended.

Roughly a third of patients receiving opioid substitute treatment were prescribed and two-thirds methadone. As previously shown, risk of death is higher at the beginning and immediately after the end of treatment, the basis for the argument that retaining patients in treatment for longer periods will save lives.

The new study shows that patients on buprenorphine had substantially lower rates of overdose death during treatment compared to those on methadone: four times lower in the first 4 weeks (0.3 percent compared with 1.24 percent) and almost twice as low during the rest of time on treatment (0.18 percent compared with 0.33 percent).

These differences remained even after adjusting for differences in patient and practice characteristics for those prescribed methadone or buprenorphine.

Patients on buprenorphine also had lower rates of all-cause mortality during and immediately after treatment – which may be because patients who are older and have other physical and mental health complications may do better on buprenorphine than methadone.

The study also confirmed that patients on buprenorphine do not stay in treatment for as long as patients on methadone. Since the benefits of treatment are greater the longer treatment lasts, this needs to be considered in relation to the choice of substitute drug.

The researchers undertook a modelling exercise to see what impact treatment duration might have at a population level. They concluded that, overall, treatment using buprenorphine alone was unlikely to reduce the risk of drug related poisoning deaths because the treatment periods are shorter than for methadone.

Professor John Macleod, joint lead author from the Centre for Academic Primary Care at the University of Bristol, said:

"Although this is a somewhat complicated picture, with lower rates of death for patients on buprenorphine offset at a population level by the shorter treatment durations, our findings clearly suggest that buprenorphine may be the safer treatment option. Because of the shorter treatment duration associated with its use, starting treatment with buprenorphine then giving patients the option to switch to methadone later could be the best approach.

"Internationally, there is no consensus about which medication to use. In the UK, the British Association for Psychopharmacology currently recommends as the first-line treatment if there are no contraindications. We believe that future guidance should take these findings into account."

Professor Matthew Hickman, from the NIHR Health Protection Research Unit and Population Health Sciences at University of Bristol, and joint lead author of the study, said:

"Despite the record number of patients in treatment, drug related deaths continue to rise. Our research provides evidence to support a change in the way treatment is delivered that could save lives. We now need trials in the UK on how we combine different opioid substitution treatments alongside other behaviour change interventions to retain people in treatment long enough to reduce the number of drug related deaths in the population."

Explore further: Methadone increases death risk in first four weeks of treatment for opioid dependence

More information: Matthew Hickman et al. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom, Addiction (2018). DOI: 10.1111/add.14188

Related Stories

Methadone increases death risk in first four weeks of treatment for opioid dependence

September 16, 2015
Patients who start treatment for dependence on opioids are five times as likely to die in the first four weeks when they are prescribed the most commonly used treatment, methadone, than with an alternative treatment, buprenorphine, ...

Slow-release oral morphine could expand options for treating opioid abuse

December 25, 2017
Slow-release oral Morphine (SROM) has emerged as a promising candidate for oral opioid agonist therapy. However, more research is needed before it can be incorporated into U.S. treatment guidelines. A commentary from the ...

Study finds opportunity to increase opioid dependence treatment in Ontario jails

February 15, 2018
A study from McMaster University suggests more can be done to improve access to and delivery of opioid dependence treatment in adult correctional facilities in Ontario.

Many patients receive prescription opioids during treatment for opioid addiction

February 23, 2017
More than two in five people receiving buprenorphine, a drug commonly used to treat opioid addiction, are also given prescriptions for other opioid painkillers - and two-thirds are prescribed opioids after their treatment ...

Study looks at physicians who prescribe methadone

July 19, 2017
A small number of physicians prescribe the majority of the drugs used to treat people in Ontario who are battling opioid addictions, a new study has found.

Study examines opioid agonist therapy use in Medicare patients

July 20, 2016
Few Medicare enrollees appear to be receiving buprenorphine-naloxone, the only opioid agonist therapy for opioid addiction available through Medicare Part D prescription drug coverage, according to a study published online ...

Recommended for you

Researchers find mice lacking gene for PTPRD self-administer less cocaine

October 23, 2018
A team with members affiliated with several institutions in the U.S. has found that disabling the gene responsible for the production of the protein tyrosine phosphatase D (PTPRD) caused test mice to self-administer less ...

Smoking cessation: A genetic mutation involved in relapse

October 4, 2018
Why is it so difficult to stop smoking? Why do some people relapse months after giving up? Scientists from the Institut Pasteur and the CNRS, in collaboration with Sorbonne University and Inserm, have demonstrated that a ...

Study shows cigarillo flavors enhanced by high-intensity sweeteners

October 3, 2018
In a new study, Yale researchers found that popular brands of cigarillos are flavored with high-intensity sweeteners, potentially reducing the aversive sensation of smoking and making cigarillos more palatable. The concern ...

Leading addiction experts call for more neuroscience research on long-term recovery

September 24, 2018
September is addiction recovery month, and, in the midst of the current opioid epidemic, it's an apt moment for addiction research experts to map the future path forward for a long-term recovery strategy for substance abuse. ...

The connection between alcoholism and depression

September 21, 2018
Alcoholism and depression often go hand-in-hand.

Quitting junk food produces similar withdrawal-type symptoms as drug addiction

September 20, 2018
If you plan to try and quit junk food, expect to suffer similar withdrawal-type symptoms—at least during the initial week—like addicts experience when they attempt to quit using drugs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.